Market Overview:

According to IMARC Group's latest research publication, "Hormonal Contraceptive Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The global hormonal contraceptive market size reached USD 19.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 26.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.48% during 2025-2033. 

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How AI is Reshaping the Future of Hormonal Contraceptive Market

• AI-Powered Personalized Contraceptive Matching: AI platforms now analyze genetic data, health history, and real-time hormone monitoring via wearables to recommend the most compatible contraceptive method. Tools like ContraceptAI (launched May 2025) utilize this approach to improve user adherence and reduce side effects for millions of women globally.
• Digital Contraceptive Apps Driving Compliance: AI-driven cycle tracking apps and telehealth platforms have achieved a 42% increase in user compliance rates (WHO, 2022–2023). Platforms like Nurx, Flo, and Natural Cycles leverage machine learning to personalize reproductive health guidance, reducing unintended pregnancies.
• Predictive Analytics in Drug Development: Pharmaceutical companies are employing AI-based predictive analytics to accelerate R&D for next-generation low-dose, side-effect-minimizing hormonal formulations. In 2024, over 27 patents were filed for novel progestin compounds designed to reduce mood-related side effects by 50%.
• Wearable Integration and Real-Time Monitoring: Wearable devices integrated with AI are emerging as adjuncts to hormonal contraceptives, offering real-time tracking of compliance and side-effect management. This convergence of FemTech and AI is improving outcomes especially for the 15–24 age group, the market's largest segment.
• AI in Supply Chain and Accessibility Optimization: Global health organizations and NGOs are utilizing AI-enabled logistics to optimize distribution of contraceptives in underserved areas, with global health bodies pledging to supply 210 million contraceptive units annually by 2025 to emerging economies, aided by AI-driven demand forecasting.

Download a sample PDF of this report: https://www.imarcgroup.com/hormonal-contraceptive-market/requestsample

Key Trends in the Hormonal Contraceptive Market

• Rising Adoption of Long-Acting Reversible Contraceptives (LARCs): The increasing preference for IUDs and hormonal implants over daily pills is a defining trend. LARCs provide extended protection of 3–10 years, reducing user dependency and improving efficacy. The U.S. Department of Health documented a 23% rise in LARC prescriptions at federally funded clinics from 2022 to 2024.
• Telehealth and Online Pharmacy Expansion: Telemedicine platforms now facilitate direct access to prescription contraceptives through home delivery and virtual consultations. Online pharmacies are a fast-growing distribution channel, driven by privacy preferences and the desire for convenience, especially among the 15–34 age group.
• Government-Backed Family Planning Initiatives: Supportive policies across developing nations are lowering contraceptive costs and expanding access. Australia invested over AUD 500 million in 2025 to reform women's health, adding new contraceptive pills to its Pharmaceutical Benefits Scheme. Such measures are widening the market's reach in Asia-Pacific.
• Shift Toward Progestin-Only and Low-Dose Formulations: Growing awareness of estrogen-related side effects is driving demand for progestin-only contraceptives among breastfeeding women and those with contraindications to estrogen. Extended-cycle pills and ultra-low-dose formulations (e.g., 20 μg EE / 3 mg DRSP in 24/4 regimens) are gaining traction.
• Multi-Purpose Contraceptive Products: Combination formulations that address contraception alongside acne, iron deficiency, and menstrual regulation are gaining popularity. In 2024, at least 9 dual-purpose hormonal products received regulatory approval in Europe, attracting over 3 million users aged 16–24.

Growth Factors in the Hormonal Contraceptive Market

• Increasing Global Awareness of Reproductive Health: According to the WHO, 1.9 billion women of reproductive age existed worldwide in 2021, of which 164 million had unmet contraceptive needs. Heightened awareness through international campaigns and NGO-driven educational programs is steadily converting this unmet need into market demand.
• Rising Women's Empowerment and Workforce Participation: As more women pursue higher education and careers globally, demand for reliable family planning tools is growing. Young women aged 15–24, the market's dominant segment, are increasingly seeking effective contraceptive options to delay parenthood and maintain autonomy over reproductive choices.
• Technological Advancements and Product Innovation: Continuous innovation in drug delivery systems—including extended-cycle pills, improved IUD designs, biodegradable implants, and transdermal patches—is enhancing user convenience and compliance. Innovations such as app-integrated blister packs with daily reminders are driving adherence and broadening adoption.
• Expanding Insurance and Healthcare Coverage: In North America and Western Europe, the inclusion of hormonal contraceptives under insurance and public health schemes is a significant growth driver. Greater affordability reduces financial barriers and improves uptake, particularly among younger demographics.
• Growing Demand in Asia-Pacific Emerging Markets: Rapid urbanization, rising disposable incomes, and government-led family planning schemes across China, India, and Southeast Asia are accelerating market growth. Asia-Pacific is expected to register the fastest regional growth in the global hormonal contraceptive market during the forecast period.

Leading Companies Operating in the Global Hormonal Contraceptive Industry:

• Afaxys Inc.
• Agile Therapeutics Inc.
• Allergan Inc. (AbbVie Inc.)
• Bayer AG
• Cipla Limited
• Johnson & Johnson
• Merck & Co. Inc.
• Pfizer Inc.
• Piramal Group
• Teva Pharmaceutical Industries Ltd.

Hormonal Contraceptive Market Report Segmentation:

Breakup By Product:

• Oral Contraceptive Pills
• Intrauterine Device (IUD)
• Injectable Birth Control
• Vaginal Rings
• Others

Oral contraceptive pills account for the majority of the market share, owing to their unmatched combination of efficacy, convenience, availability, and a long history of safe use worldwide.

Breakup By Hormone:

• Progestin-only Contraceptive
• Combined Hormonal Contraceptive

Combined hormonal contraceptive holds the largest share due to its high efficacy, diverse formulation options (pills, rings, patches), and additional health benefits such as regulated menstrual cycles and reduced cancer risk.

Breakup By Age Group:

• 15-24 Years
• 25-34 Years
• 35-44 Years
• Above 44 Years

The 15–24 years segment represents the largest group, driven by increased sexual activity, broad educational outreach, and the desire to pursue education and career before starting a family.

Breakup By End User:

• Hospitals and Clinics
• Homecare
• Ambulatory Surgical Centers
• Others

Homecare exhibits a clear dominance in the market, reflecting consumer preference for privacy, self-administration, and the growing availability of contraceptives through online platforms and telehealth services.

Breakup By Region:

• North America (United States, Canada)
• Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America leads the market owing to well-developed healthcare infrastructure, high awareness, strong government support, and widespread insurance coverage for contraceptives.

Recent News and Developments in Hormonal Contraceptive Market

• April 2024: Merck & Co. Inc. announced an investment of over €300 million (USD 320.8 million) to establish a new Life Science Research Center at its headquarters in Darmstadt, Germany, underscoring its commitment to reproductive health R&D.
• March 2024: Perrigo Company plc announced the U.S. availability of Opill, its oral contraceptive pill, now offered over-the-counter without a prescription and accessible via online sales — a milestone in improving contraceptive accessibility and convenience for consumers.
• May 2025: Health researchers and tech companies launched ContraceptAI, an AI-powered platform utilizing genetic testing, health history, and real-time hormone monitoring via wearables to recommend the most compatible hormonal contraceptive options for individual users.
• February 2025: The Australian Government committed over AUD 500 million to reform women's health, including adding new contraceptive pills to the Pharmaceutical Benefits Scheme (PBS) and increasing Medicare rebates for contraceptive devices, boosting market access in the Asia-Pacific region.
• January 2022: Agile Therapeutics, Inc. entered a new partnership with Afaxys Pharma, LLC to support the promotion of Twirla® — a levonorgestrel and ethinyl estradiol transdermal contraceptive patch system — expanding its commercial footprint in the U.S. market.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

 

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302